Topic: Amyotrophic Lateral Sclerosis

Interventions of Interest: The majority of independent appraisal committee voted that the evidence is adequate to demonstrate that both AMX0035 and oral edaravone (in population narrower than its label) provide a net health benefit compared to standard of care. They also determined that at current pricing or price estimates both therapies represent a “low” long-term […]